Paper35330833
Comparative Efficacy of Different Drugs for Lower Urinary Tract Symptoms due to Benign Prostatic Hyperplasia: A Bayesian Network Meta-Analysis.
Fan Z and 4 others. Front Pharmacol, 2022. Cited by 9 papers, by iCite.
Cite this record
ConductScience Library. Comparative Efficacy of Different Drugs for Lower Urinary Tract Symptoms due to Benign Prostatic Hyperplasia: A Bayesian Network Meta-Analysis. Papers, record 35330833. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/35330833
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Comparative Efficacy of Different Drugs for Lower Urinary Tract Symptoms due to Benign Prostatic Hyperplasia: A Bayesian Network Meta-Analysis.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Comment in | 35950379 | Benign Prostatic Hyperplasia. | https://conductscience.org/library/papers/35950379 |
Source PubMed
References77
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 30574201 | Mirabegron, alone and in combination, in the treatment of overactive bladder: real-world evidence and experience. | Ther Adv Urol | 2018 | https://conductscience.org/library/papers/30574201 | PubMed |
| 2 | 17211442 | Rapid onset of action with alfuzosin 10 mg once daily in men with benign prostatic hyperplasia: a randomized, placebo-controlled trial. | Prostate Cancer Prostatic Dis | 2007 | https://conductscience.org/library/papers/17211442 | PubMed |
| 3 | 21871706 | Efficacy and safety of tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double-blind, placebo-controlled trial. | Eur Urol | 2011 | https://conductscience.org/library/papers/21871706 | PubMed |
| 4 | 28508455 | A multicenter real-life study of the efficacy of an alpha-blocker with or without anticholinergic agent (imidafenacin) treatment in patients with lower urinary tract symptoms/benign prostatic hyperplasia and storage symptoms. | Int J Clin Pract | 2017 | https://conductscience.org/library/papers/28508455 | PubMed |
| 5 | 12887479 | Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies. | BJU Int | 2003 | https://conductscience.org/library/papers/12887479 | PubMed |
| 6 | 26030634 | The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. | Ann Intern Med | 2015 | https://conductscience.org/library/papers/26030634 | PubMed |
| 7 | 22405510 | A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia. | Eur Urol | 2012 | https://conductscience.org/library/papers/22405510 | PubMed |
| 8 | 17010005 | Naftopidil monotherapy vs naftopidil and an anticholinergic agent combined therapy for storage symptoms associated with benign prostatic hyperplasia: A prospective randomized controlled study. | Int J Urol | 2006 | https://conductscience.org/library/papers/17010005 | PubMed |
| 9 | 26211817 | Tamsulosin combined with solifenacin versus tamsulosin monotherapy for male lower urinary tract symptoms: a meta-analysis. | Curr Med Res Opin | 2015 | https://conductscience.org/library/papers/26211817 | PubMed |
| 10 | 10720857 | Efficacy and safety of a new prolonged release formulation of alfuzosin 10 mg once daily versus alfuzosin 2.5 mg thrice daily and placebo in patients with symptomatic benign prostatic hyperplasia. ALFORTI Study Group. | Eur Urol | 2000 | https://conductscience.org/library/papers/10720857 | PubMed |
| 11 | 18281145 | A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. | Eur Urol | 2008 | https://conductscience.org/library/papers/18281145 | PubMed |
| 12 | 18638006 | Comparative efficacy assessment of tamsulosin vs. tamsulosin plus tadalafil in the treatment of LUTS/BPH. Pilot study. | J Sex Med | 2008 | https://conductscience.org/library/papers/18638006 | PubMed |
| 13 | 32110593 | Study of correlation of urodynamic profile with symptom scoring and ultrasonographic parameters in patients with benign prostatic hyperplasia. | J Family Med Prim Care | 2020 | https://conductscience.org/library/papers/32110593 | PubMed |
| 14 | 22704110 | Incidence and progression of lower urinary tract symptoms in a large prospective cohort of United States men. | J Urol | 2012 | https://conductscience.org/library/papers/22704110 | PubMed |
| 15 | 15839922 | Efficacy and safety of two doses (10 and 15 mg) of alfuzosin or tamsulosin (0.4 mg) once daily for treating symptomatic benign prostatic hyperplasia. | BJU Int | 2005 | https://conductscience.org/library/papers/15839922 | PubMed |
| 16 | 30251330 | Effect of tadalafil add-on therapy in patients with persistant storage symptoms refractory to α1 -adrenoceptor antagonist monotherapy for benign prostatic hyperplasia: A randomized pilot trial comparing tadalafil and solifenacin. | Low Urin Tract Symptoms | 2019 | https://conductscience.org/library/papers/30251330 | PubMed |
| 17 | 21109344 | Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe. | Eur Urol | 2011 | https://conductscience.org/library/papers/21109344 | PubMed |
| 18 | 34879880 | Epidemiological trends of urinary tract infections, urolithiasis and benign prostatic hyperplasia in 203 countries and territories from 1990 to 2019. | Mil Med Res | 2021 | https://conductscience.org/library/papers/34879880 | PubMed |
| 19 | 23953605 | Clinical efficacy and safety of imidafenacin as add-on treatment for persistent overactive bladder symptoms despite α-blocker treatment in patients with BPH: the ADDITION study. | Urology | 2013 | https://conductscience.org/library/papers/23953605 | PubMed |
| 20 | 19070418 | Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers. | Eur Urol | 2009 | https://conductscience.org/library/papers/19070418 | PubMed |
Cited by7
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 9 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41879994 | [Pharmacotherapy of benign prostatic syndrome : Medications, innovations and future prospects]. | Urologie | 2026 | https://conductscience.org/library/papers/41879994 | PubMed |
| 41305716 | Identification of biomarkers of Shenhailong formula in benign prostatic hyperplasia treatment: An observation study using network pharmacology and Mendelian randomization analysis. | Medicine (Baltimore) | 2025 | https://conductscience.org/library/papers/41305716 | PubMed |
| 40873873 | Comparative efficacy and safety of silodosin and tadalafil combination or monotherapy for treating lower urinary tract symptoms due to benign prostatic obstruction: A systematic review and meta-analysis. | Cent European J Urol | 2025 | https://conductscience.org/library/papers/40873873 | PubMed |
| 40301381 | Associations between the risk of LUTS/BPH and the number and class of chronic diseases among middle-aged and elder men. | Sci Rep | 2025 | https://conductscience.org/library/papers/40301381 | PubMed |
| 39789390 | Technological innovation of HoLEP: a multicenter, randomized, controlled study for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. | World J Urol | 2025 | https://conductscience.org/library/papers/39789390 | PubMed |
| 38158423 | A correlation study between prostate necrosis rate calculated by 3D Slicer software and clinical efficacy of prostatic artery embolization, along with an analysis of predictors of clinical success after prostatic artery embolization. | Abdom Radiol (NY) | 2024 | https://conductscience.org/library/papers/38158423 | PubMed |
| 37943844 | Diacerein provokes apoptosis, improves redox balance, and downregulates PCNA and TNF-α in a rat model of testosterone-induced benign prostatic hyperplasia: A new non-invasive approach. | PLoS One | 2023 | https://conductscience.org/library/papers/37943844 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| ADRB3 | 155 | PubTator's text mining | https://conductscience.org/library/genes/155 | NCBI Gene |
| PDE5A | 8654 | PubTator's text mining | https://conductscience.org/library/genes/8654 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/35330833
GET https://conductscience.org/api/papers/v1/35330833/references?page=2